VTGN - Vistagen climbs as Stifel launches at Buy on anxiety prospects
2023-11-14 15:18:06 ET
More on VistaGen Therapeutics
- Vistagen Therapeutics, Inc. (VTGN) Q2 2024 Earnings Call Transcript
- VistaGen Therapeutics GAAP EPS of -$0.66 beats by $0.02, revenue of $0.28M
- Vistagen prices $100M underwritten offering
- Seeking Alpha’s Quant Rating on VistaGen Therapeutics
- Historical earnings data for VistaGen Therapeutics
For further details see:
Vistagen climbs as Stifel launches at Buy on anxiety prospects